$CUE
Cue Biopharma Inc

2024 Q3 Form 10-Q Financial Statement

#000095017024096967 Filed on August 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $2.658M
YoY Change 92.33%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.511M
YoY Change -17.37%
% of Gross Profit
Research & Development $9.530M
YoY Change -10.52%
% of Gross Profit
Depreciation & Amortization $100.0K
YoY Change -24.24%
% of Gross Profit
Operating Expenses $13.04M
YoY Change -12.47%
Operating Profit -$10.38M
YoY Change -23.19%
Interest Expense $427.0K
YoY Change 22.0%
% of Operating Profit
Other Income/Expense, Net $212.0K
YoY Change -36.14%
Pretax Income -$10.17M
YoY Change -22.86%
Income Tax
% Of Pretax Income
Net Earnings -$10.17M
YoY Change -22.86%
Net Earnings / Revenue -382.66%
Basic Earnings Per Share -$0.20
Diluted Earnings Per Share -$0.20
COMMON SHARES
Basic Shares Outstanding 48.64M 48.64M
Diluted Shares Outstanding 50.17M

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $60.03M
YoY Change 3.7%
Cash & Equivalents $30.03M
Short-Term Investments $30.00M
Other Short-Term Assets $2.024M
YoY Change 5.91%
Inventory
Prepaid Expenses
Receivables $1.847M
Other Receivables $0.00
Total Short-Term Assets $33.90M
YoY Change -44.37%
LONG-TERM ASSETS
Property, Plant & Equipment $667.0K
YoY Change -44.04%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $111.0K
YoY Change -9.76%
Total Long-Term Assets $8.429M
YoY Change -31.07%
TOTAL ASSETS
Total Short-Term Assets $33.90M
Total Long-Term Assets $8.429M
Total Assets $42.33M
YoY Change -42.14%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.906M
YoY Change 65.79%
Accrued Expenses $4.562M
YoY Change 11.92%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due $4.000M
YoY Change 0.0%
Total Short-Term Liabilities $16.46M
YoY Change 0.93%
LONG-TERM LIABILITIES
Long-Term Debt $2.286M
YoY Change -62.63%
Other Long-Term Liabilities $1.962M
YoY Change -58.56%
Total Long-Term Liabilities $2.286M
YoY Change -62.63%
TOTAL LIABILITIES
Total Short-Term Liabilities $16.46M
Total Long-Term Liabilities $2.286M
Total Liabilities $20.71M
YoY Change -23.76%
SHAREHOLDERS EQUITY
Retained Earnings -$323.7M
YoY Change 16.97%
Common Stock $345.3M
YoY Change 6.99%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $21.62M
YoY Change
Total Liabilities & Shareholders Equity $42.33M
YoY Change -42.14%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$10.17M
YoY Change -22.86%
Depreciation, Depletion And Amortization $100.0K
YoY Change -24.24%
Cash From Operating Activities -$9.990M
YoY Change -3.67%
INVESTING ACTIVITIES
Capital Expenditures $10.00K
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change -100.0%
Cash From Investing Activities -$10.00K
YoY Change -100.2%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -1.000M
YoY Change -147.6%
NET CHANGE
Cash From Operating Activities -9.990M
Cash From Investing Activities -10.00K
Cash From Financing Activities -1.000M
Net Change In Cash -11.00M
YoY Change 236.39%
FREE CASH FLOW
Cash From Operating Activities -$9.990M
Capital Expenditures $10.00K
Free Cash Flow -$10.00M
YoY Change -3.58%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001645460
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2023#LicenseMember
us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2023#LicenseMember
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38327
dei Entity Registrant Name
EntityRegistrantName
Cue Biopharma, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-3324577
dei Entity Address Address Line1
EntityAddressAddressLine1
40 Guest Street
dei Entity Address City Or Town
EntityAddressCityOrTown
Boston
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02135
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
949-2680
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
CUE
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
48643316
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
30029000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
48514000
CY2024Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1847000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1698000
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2024000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1242000
CY2024Q2 us-gaap Assets Current
AssetsCurrent
33900000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
51454000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
667000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
795000
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4810000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
6323000
CY2024Q2 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
2690000
CY2023Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
2690000
CY2024Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
151000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
151000
CY2024Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
111000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
117000
CY2024Q2 us-gaap Assets
Assets
42329000
CY2023Q4 us-gaap Assets
Assets
61530000
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
3906000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3501000
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4562000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4137000
CY2024Q2 cue Research And Development Contract Liability Current
ResearchAndDevelopmentContractLiabilityCurrent
976000
CY2023Q4 cue Research And Development Contract Liability Current
ResearchAndDevelopmentContractLiabilityCurrent
2112000
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3052000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3368000
CY2024Q2 us-gaap Other Long Term Debt Current
OtherLongTermDebtCurrent
3963000
CY2023Q4 us-gaap Other Long Term Debt Current
OtherLongTermDebtCurrent
3963000
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
16459000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
17081000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1962000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3162000
CY2024Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
2286000
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
4202000
CY2024Q2 us-gaap Liabilities
Liabilities
20707000
CY2023Q4 us-gaap Liabilities
Liabilities
24445000
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
48643316
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
48643316
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
47215116
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
47215116
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
48000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
47000
CY2024Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
345282000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
338228000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-323708000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-301190000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
21622000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
37085000
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
42329000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
61530000
CY2024Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2658000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1382000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4375000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1570000
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3511000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4249000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7697000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8425000
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9530000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10650000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19729000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20041000
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
13041000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
14899000
us-gaap Operating Expenses
OperatingExpenses
27426000
us-gaap Operating Expenses
OperatingExpenses
28466000
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-10383000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-13517000
us-gaap Operating Income Loss
OperatingIncomeLoss
-23051000
us-gaap Operating Income Loss
OperatingIncomeLoss
-26896000
CY2024Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
427000
CY2023Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
564000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
989000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1056000
CY2024Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-215000
CY2023Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-232000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-456000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-454000
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
212000
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
332000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
533000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
602000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-10171000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-13185000
us-gaap Net Income Loss
NetIncomeLoss
-22518000
us-gaap Net Income Loss
NetIncomeLoss
-26294000
CY2024Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
0
CY2023Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
34000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
0
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
91000
CY2024Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10171000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13151000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-22518000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-26203000
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.2
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.2
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.29
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.29
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.45
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.45
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.59
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.59
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
50174756
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
50174756
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44798760
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44798760
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
49822689
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
49822689
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44725875
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44725875
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
55017000
CY2023Q2 cue Issuance Of Common Stock From Atm Offering Net Of Sales Agent Commission And Fees Amount
IssuanceOfCommonStockFromAtmOfferingNetOfSalesAgentCommissionAndFeesAmount
2016000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2037000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
85000
CY2023Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
34000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-13185000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
46004000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
30038000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1755000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-10171000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
21622000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
65683000
cue Issuance Of Common Stock From Atm Offering Net Of Sales Agent Commission And Fees Amount
IssuanceOfCommonStockFromAtmOfferingNetOfSalesAgentCommissionAndFeesAmount
2016000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4035000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
473000
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
91000
us-gaap Net Income Loss
NetIncomeLoss
-26294000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
46004000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
37085000
cue Issuance Of Common Stock From Atm Offering Net Of Sales Agent Commission And Fees Amount
IssuanceOfCommonStockFromAtmOfferingNetOfSalesAgentCommissionAndFeesAmount
3354000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3701000
us-gaap Net Income Loss
NetIncomeLoss
-22518000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
21622000
us-gaap Profit Loss
ProfitLoss
-22518000
us-gaap Profit Loss
ProfitLoss
-26294000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
198000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
313000
us-gaap Share Based Compensation
ShareBasedCompensation
3701000
us-gaap Share Based Compensation
ShareBasedCompensation
4035000
cue Change In Operating Lease Right Of Use Asset
ChangeInOperatingLeaseRightOfUseAsset
1513000
cue Change In Operating Lease Right Of Use Asset
ChangeInOperatingLeaseRightOfUseAsset
1416000
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-1000
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
2000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
0
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
-222000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
18000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
18000
cue Accretion Of Final Payment On Term Loan
AccretionOfFinalPaymentOnTermLoan
65000
cue Accretion Of Final Payment On Term Loan
AccretionOfFinalPaymentOnTermLoan
65000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
149000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1077000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
782000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1070000
cue Increase Decrease In Deposit Liabilities
IncreaseDecreaseInDepositLiabilities
0
cue Increase Decrease In Deposit Liabilities
IncreaseDecreaseInDepositLiabilities
139000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
405000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-375000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
426000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
521000
cue Increase Decrease In Research And Development Contract Liability
IncreaseDecreaseInResearchAndDevelopmentContractLiability
-1136000
cue Increase Decrease In Research And Development Contract Liability
IncreaseDecreaseInResearchAndDevelopmentContractLiability
2683000
cue Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-1516000
cue Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-1354000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-19774000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-21204000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
65000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
2000
cue Payments For Redemption Of Short Term Investments
PaymentsForRedemptionOfShortTermInvestments
0
cue Payments For Redemption Of Short Term Investments
PaymentsForRedemptionOfShortTermInvestments
-20000000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-65000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
20002000
cue Proceeds From At Time Market Offering Net Of Commission And Fees
ProceedsFromAtTimeMarketOfferingNetOfCommissionAndFees
3354000
cue Proceeds From At Time Market Offering Net Of Commission And Fees
ProceedsFromAtTimeMarketOfferingNetOfCommissionAndFees
2016000
cue Payment Of Term Loan
PaymentOfTermLoan
-2000000
cue Payment Of Term Loan
PaymentOfTermLoan
0
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
473000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1354000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2489000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-18485000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1287000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
48665000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
51764000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
30180000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
53051000
us-gaap Interest Paid Net
InterestPaidNet
392000
us-gaap Interest Paid Net
InterestPaidNet
506000
CY2024Q2 us-gaap Marketable Securities
MarketableSecurities
30000000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates include estimates related to collaboration revenue, the accounting for potential liabilities and accrued expenses, the assumptions utilized in valuing stock-based compensation issued for services, the realization of deferred tax assets, and the useful life with respect to long-lived assets and intangibles. Actual results could differ from those estimates.</span></p>
CY2024Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
0
CY2023Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
0
us-gaap Acquired Finite Lived Intangible Assets Weighted Average Useful Life
AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
P15Y
cue Pre Funded Warrants
PreFundedWarrants
1531440
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
18651314
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
16293081
CY2024Q2 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
30000000
CY2023Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
39100000
CY2024Q2 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
30000000
CY2023Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
39100000
CY2024Q2 cue Fair Value Assets Among Level2 And Level3 Transfers Amount
FairValueAssetsAmongLevel2AndLevel3TransfersAmount
0
CY2023Q4 cue Fair Value Assets Among Level2 And Level3 Transfers Amount
FairValueAssetsAmongLevel2AndLevel3TransfersAmount
0
CY2024Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4470000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4411000
CY2024Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3803000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3616000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
667000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
795000
CY2024Q2 us-gaap Depreciation
Depreciation
100000
CY2023Q2 us-gaap Depreciation
Depreciation
100000
us-gaap Depreciation
Depreciation
200000
us-gaap Depreciation
Depreciation
300000
CY2024Q2 cue Amortization Of Trademark
AmortizationOfTrademark
3000
CY2023Q2 cue Amortization Of Trademark
AmortizationOfTrademark
3000
cue Amortization Of Trademark
AmortizationOfTrademark
6000
cue Amortization Of Trademark
AmortizationOfTrademark
6000
CY2024Q2 us-gaap Interest Expense Other
InterestExpenseOther
200000
us-gaap Interest Expense Other
InterestExpenseOther
400000
CY2024Q2 us-gaap Repayments Of Debt
RepaymentsOfDebt
33000
us-gaap Repayments Of Debt
RepaymentsOfDebt
65000
CY2023Q2 us-gaap Interest Expense Other
InterestExpenseOther
400000
us-gaap Interest Expense Other
InterestExpenseOther
600000
CY2023Q2 us-gaap Repayments Of Debt
RepaymentsOfDebt
33000
us-gaap Repayments Of Debt
RepaymentsOfDebt
65000
CY2024Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
2000000
CY2024Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
4000000
CY2024Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
6000000
CY2024Q2 us-gaap Long Term Debt
LongTermDebt
2000000
CY2024Q2 cue Accretion Of Final Payment
AccretionOfFinalPayment
305000
CY2024Q2 us-gaap Deferred Finance Costs Current Gross
DeferredFinanceCostsCurrentGross
19000
CY2024Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
2286000
CY2024Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
4000000
CY2024Q2 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
-37000
CY2024Q2 us-gaap Other Long Term Debt Current
OtherLongTermDebtCurrent
3963000
CY2023Q2 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
142000
CY2024Q2 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
9000
CY2023Q2 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
9000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
18000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
18000
CY2024Q2 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
1429000
CY2023Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
2219000
CY2024Q2 cue Accrued Contract Research Services Current
AccruedContractResearchServicesCurrent
2109000
CY2023Q4 cue Accrued Contract Research Services Current
AccruedContractResearchServicesCurrent
1411000
CY2024Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
309000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
344000
CY2024Q2 cue Accrued Contract Manufacturing Services Current
AccruedContractManufacturingServicesCurrent
715000
CY2023Q4 cue Accrued Contract Manufacturing Services Current
AccruedContractManufacturingServicesCurrent
163000
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4562000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4137000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0383
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0443
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.501
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.0986
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.034
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0399
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.9703
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.038
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
7492917
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.41
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y1M13D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2463300
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.93
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
493309
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
6.04
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
9462908
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.84
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y8M15D
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4938832
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
9.98
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P4Y9M
CY2024Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
9200000
CY2023Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
11000000
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
593800
CY2024Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
1.65
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
2463300
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
1.93
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
140000
CY2023Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
3.75
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
1461900
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
3.25
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1755000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2037000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3701000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4035000
CY2019Q2 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
2500000
CY2019Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
400000
CY2020Q4 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
1250000
CY2021Q4 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
3000000
CY2024Q2 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
100000
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
200000
CY2023Q2 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
100000
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
300000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1669000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2799000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
818000
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
5286000
CY2024Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
272000
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
5014000
CY2024Q2 cue Operating Leases Rent Expenses Net
OperatingLeasesRentExpensesNet
900000
CY2023Q2 cue Operating Leases Rent Expenses Net
OperatingLeasesRentExpensesNet
900000
cue Operating Leases Rent Expenses Net
OperatingLeasesRentExpensesNet
1700000
cue Operating Leases Rent Expenses Net
OperatingLeasesRentExpensesNet
1700000
CY2024Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y8M15D
CY2023Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y1M28D
CY2024Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0609
CY2023Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0625
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000950170-24-096967-index-headers.html Edgar Link pending
0000950170-24-096967-index.html Edgar Link pending
0000950170-24-096967.txt Edgar Link pending
0000950170-24-096967-xbrl.zip Edgar Link pending
cue-20240630.htm Edgar Link pending
cue-20240630.xsd Edgar Link pending
cue-ex10_1.htm Edgar Link pending
cue-ex10_2.htm Edgar Link pending
cue-ex31_1.htm Edgar Link pending
cue-ex31_2.htm Edgar Link pending
cue-ex32_1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img77947453_0.jpg Edgar Link pending
img77947453_1.jpg Edgar Link pending
img77947453_2.jpg Edgar Link pending
img77947453_3.jpg Edgar Link pending
img77947453_4.jpg Edgar Link pending
img77947453_5.jpg Edgar Link pending
img77947453_6.jpg Edgar Link pending
img77947453_7.jpg Edgar Link pending
img77947453_8.jpg Edgar Link pending
img77947453_9.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
cue-20240630_htm.xml Edgar Link completed
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable